214 related articles for article (PubMed ID: 11296615)
1. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
[TBL] [Abstract][Full Text] [Related]
2. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
Büntzel J; Küttner K; Fröhlich D; Glatzel M
Ann Oncol; 1998 May; 9(5):505-9. PubMed ID: 9653491
[TBL] [Abstract][Full Text] [Related]
3. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277
[TBL] [Abstract][Full Text] [Related]
4. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
8. [Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Büntzel J; Glatzel M; Schuth J; Weinaug R; Küttner K; Fröhlich D
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():37-40. PubMed ID: 10584140
[TBL] [Abstract][Full Text] [Related]
9. Radiochemotherapy with amifostine cytoprotection for head and neck cancer.
Büntzel J; Schuth J; Küttner K; Glatzel M
Support Care Cancer; 1998 Mar; 6(2):155-60. PubMed ID: 9540175
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
12. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
14. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
[TBL] [Abstract][Full Text] [Related]
15. Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
Peters K; Mücke R; Hamann D; Ziegler PG; Fietkau R
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():23-6. PubMed ID: 10584136
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
[TBL] [Abstract][Full Text] [Related]
17. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Braaksma M; Levendag P
Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
[TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
[TBL] [Abstract][Full Text] [Related]
19. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
Haddad R; Wirth L; Costello R; Weeks L; Posner M
Semin Oncol; 2003 Dec; 30(6 Suppl 18):84-8. PubMed ID: 14727246
[TBL] [Abstract][Full Text] [Related]
20. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
